The acquisition gives Johnson & Johnson access to Firefly Bio’s next-gen platform designed to create degrader antibody conjugates that can crack the tricky KRAS cancer target.
Incyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has “pipeline-in-a-product” potential.
After a $625 million IPO, the biggest ever in biotech, obesity-focused Kailera Therapeutics is readying a commercial strategy that puts patients at the center.
Corporate restatements dropped by almost a fifth in 2025, according to a report from Ideagen Audit Analytics, continuing a long-term over trend of decreases.
Employers added a 172,00 jobs overall last month, but there were job losses in some sectors, including accounting, tax, bookkeeping and payroll services.